Long-term Survival After Radiofrequency Ablation of Complex Unresectable Liver Tumors
- 1 June 2006
- journal article
- research article
- Published by American Medical Association (AMA) in Archives of Surgery
- Vol. 141 (6), 581-588
- https://doi.org/10.1001/archsurg.141.6.581
Abstract
Hypothesis Radiofrequency ablation (RFA) may improve survival of high-risk patients with unresectable and refractory tumors. Design Retrospective analysis of a prospective database. Setting A tertiary referral cancer center. Patients and Methods Between November 1, 1997, and January 31, 2005, we performed 219 RFA procedures to ablate 521 hepatic tumors in 181 patients. Results Of the 181 patients, 52% were male and 48% were female, and the mean age was 61.3 years (age range, 27-91 years). Radiofrequency ablation was performed via celiotomy (n = 135), via laparoscopy (n = 48), or percutaneously (n = 36). In 106 patients (79%), RFA was used in combination with surgical resection. The most common tumors included colorectal cancer (40.9%), hepatocellular carcinoma (14.9%), carcinoid tumor (13.8%), melanoma (9.4%), and breast cancer (5.0%). The average number of tumors per patient was 3.3 tumors. The average number of RFA-treated lesions per procedure was 2.38 lesions; the mean lesion size was 3.56 cm (lesion size range, 0.8-9.0 cm). At a mean follow-up of 33.2 months (follow-up range, 12-91 months), overall survival was 48.3 months for carcinoid tumors, 25.2 months for hepatocellular carcinoma, 18.5 months for melanoma, 29.7 months for colorectal cancer, and 30.1 months for breast cancer. Seventy-eight patients (43%) developed recurrences. Of 521 tumors that were treated, 125 (24%) recurred; the incidence of local recurrence was 28% for tumors larger than 3 cm vs 18% for tumors 3 cm or smaller (P = .04). Twenty-nine patients underwent serial ablations. Seventy-one patients (39%) were disease free at last follow-up. Conclusion A significant number of patients whose hepatic malignancies are unresectable or refractory to chemotherapy may be considered for RFA as part of a multimodality therapeutic regimen. In these patients, RFA is safe and may prolong survival.Keywords
This publication has 18 references indexed in Scilit:
- Is Hepatic Resection for Large or Multinodular Hepatocellular Carcinoma Justified? Results From a Multi-Institutional DatabaseAnnals of Surgical Oncology, 2005
- The Significance and Clinical Factors Associated With a Subcentimeter Resection of Colorectal Liver MetastasesAnnals of Surgical Oncology, 2005
- Long-term Survival After An Aggressive Surgical Approach in Patients With Breast Cancer Hepatic MetastasesAnnals of Surgical Oncology, 2004
- Laparoscopic Radiofrequency Ablation of Liver Tumors Combined With Colorectal ProceduresSurgical Laparoscopy, Endoscopy & Percutaneous Techniques, 2004
- Recurrence and Outcomes Following Hepatic Resection, Radiofrequency Ablation, and Combined Resection/Ablation for Colorectal Liver MetastasesAnnals of Surgery, 2004
- Combined Resection and Radiofrequency Ablation for Advanced Hepatic Malignancies: Results in 172 PatientsAnnals of Surgical Oncology, 2003
- Radiofrequency Ablation in 447 Complex Unresectable Liver Tumors: Lessons LearnedAnnals of Surgical Oncology, 2003
- Radiofrequency ablation for unresectable hepatic tumorsThe American Journal of Surgery, 2001
- Safety and Efficacy of Radiofrequency Thermal Ablation in Advanced Liver TumorsArchives of Surgery, 2001
- Radiofrequency ablation of 231 unresectable hepatic tumors: Indications, limitations, and complicationsAnnals of Surgical Oncology, 2000